Amarin Corp Plcuk (AMRN) Gains from Investment Securities (2011 - 2026)
Amarin Corp Plcuk (AMRN) reported Gains from Investment Securities of $30.8 million for Q1 2026, up 1726.45% year-over-year from $1.7 million in Q1 2025, and up 308303.0% quarter-over-quarter from -$10000.0 in Q4 2025.
Amarin Corp Plcuk (AMRN) Gains from Investment Securities (2011 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 16 years of Gains from Investment Securities data on file, last reported at $30.8 million in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $30.8 million, up 1726.45% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.8 million (up 1726.45% YoY), and the FY2025 annual result was $4.1 million, down 85.33% from the prior year.
- Gains from Investment Securities improved to $30.8 million in Q1 2026 per AMRN's latest filing, from -$10000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $30.8 million in Q1 2026 and troughed at -$10000.0 in Q4 2025.
- A 5-year average of $4.4 million and a median of $990070.0 in 2024 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2024 and 2025: Gains from Investment Securities jumped 18611.11% in 2024, then sank 100.59% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $2.5 million in 2022, then sank by 99.64% to $9000.0 in 2023, then jumped by 18611.11% to $1.7 million in 2024, then sank by 100.59% to -$10000.0 in 2025, then jumped by 308303.0% to $30.8 million in 2026.
- Business Quant data shows AMRN's Gains from Investment Securities at $30.8 million in Q1 2026, -$10000.0 in Q4 2025, and $30.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.82 Mn |
| Mar 31, 2026 | 30.82 Mn |
| Dec 31, 2025 | -10,000.00 |
| Dec 31, 2025 | -10,000.00 |
| Sep 30, 2025 | 30.77 Mn |
| Sep 30, 2025 | 30.77 Mn |
| Jun 30, 2025 | 750,000.00 |
| Jun 30, 2025 | 750,000.00 |
| Mar 31, 2025 | 1.69 Mn |
| Mar 31, 2025 | 1.69 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Dec 31, 2024 | 1.68 Mn |
| Sep 30, 2024 | 227,380.00 |
| Sep 30, 2024 | 227,380.00 |
| Jun 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 990,070.00 |
| Mar 31, 2024 | 990,070.00 |
| Dec 31, 2023 | 9,000.00 |
| Dec 31, 2023 | 9,000.00 |